Sei Investments Co. Sells 43,155 Shares of Organon & Co. (NYSE:OGN)

Sei Investments Co. trimmed its position in shares of Organon & Co. (NYSE:OGN) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 644,136 shares of the company’s stock after selling 43,155 shares during the period. Sei Investments Co. owned approximately 0.25% of Organon & Co. worth $9,610,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Horizon Bancorp Inc. IN increased its position in shares of Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares during the period. Millstone Evans Group LLC acquired a new stake in Organon & Co. during the fourth quarter worth $29,000. Larson Financial Group LLC increased its holdings in Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after buying an additional 1,734 shares during the period. Riverview Trust Co raised its stake in shares of Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after buying an additional 1,292 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after buying an additional 672 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of Organon & Co. stock opened at $14.52 on Monday. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of 4.36, a P/E/G ratio of 0.90 and a beta of 0.76. The firm’s 50-day moving average price is $15.33 and its two-hundred day moving average price is $16.21. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, equities analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.72%. Organon & Co.’s dividend payout ratio is 33.63%.

Analyst Ratings Changes

OGN has been the topic of a number of analyst reports. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Morgan Stanley lowered their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. Finally, Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.